| INTRODUCTION
The hepatitis E virus (HEV) is most commonly transmitted faecalorally, although parenteral transmission also occurs. Although HEV infection was previously thought to be rare, increasing reports from both endemic and nonendemic countries are being described, and though initially thought to be a self-limiting disease, cases of chronic infection in immunosuppressed patients are increasing, leading to cirrhosis requiring liver transplantation, and at times, fulminant liver failure or severe extrahepatic manifestations. [1] [2] [3] [4] Transfusion of blood products and maintenance haemodialysis (HD) have been implicated as potential sources of transmission. 5, 6 However, results of studies that evaluated the seroprevalence of HEV in HD patients are conflicting, reporting ranges from 0% in Ireland 7 to as high as 44% in India. 8 Some studies demonstrate statistically significant higher rate of anti-HEV IgG in HD patients versus control groups, 6,9 while others did not. 10, 11 While intuitively, this may seem related to the endemic prevalence of HEV infection in the general population, it is unclear how this prevalence changes in susceptible and immunosuppressed HD patients.
Moreover, the risk factors for HEV transmission in HD patients are unknown. If higher seroprevalence of HEV infection in HD patients is ascertained, screening for HEV infection prior to HD could be of interest. This is of particular relevance in the renal transplant population, as reports of acute hepatitis in immunosuppressed transplant recipients mount. 12 Post-transplant HEV infection can also become chronic and refractory to treatment making identification and treatment of infection before transplant ideal.
Prevention of infection with HEV vaccine could be offered if its efficacy is proven in this cohort.
| OBJECTIVE
We performed a systematic review and meta-analysis of HEV seroprevalence in HD patients, as compared with controls.
| ME TH ODS
This systematic revue and meta-analysis is reported in line with the guidelines of the preferred reporting items for systematic reviews and meta-analyses 13 with an a priori study protocol (Table S1 ). (Table S2 ). In addition, we searched the first 300 entries of Google Scholar using the terms "hepatitis E" and "haemodialysis/ hemodialysis" to look for articles not indexed in major databases.
| Data sources and search strategies
Reference lists were manually reviewed for additional cases.
Authors were contacted in cases of missing information.
3.2 | Inclusion criteria and definitions
| Included studies
We included observational studies that evaluated HEV seroprevalence (anti-HEV IgG) in HD patients in comparison to a control group (cross-sectional studies with control group, case-control studies and cohort studies).
| Included controls
Controls selected preferably from the general population (healthy volunteers or blood donors) or from other groups if they were not selected from the general population.
| Included patients
Patients in end-stage renal disease on maintenance HD regardless of age.
| Seroprevalence of HEV infection
This is based on the presence of anti-HEV IgG tested by different assays.
| Diagnosis of acute HEV infection
This is based on the presence of anti-HEV IgM tested by different assays with or without confirmation by HEV ribonucleic acid in blood or stool.
| Endemicitiy
We classified all studies according to the Centers for Disease Control and Prevention definition, wherein three levels of endemicity are identified: 1-Highly endemic areas: defined as those having had either a confirmed water-borne outbreak or confirmed HEV-infection in ≥25% of sporadic non-A, non-B hepatitis, 2-Endemic: defined as those having confirmed HEV-infection in <25% of sporadic non-A, non-B hepatitis, 3-not endemic.
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| Exclusion criteria
We excluded duplicated studies and studies that did not have a control group because they do not allow the estimation of a measure of association.
| Data extraction
Two reviewers (SH, FB) evaluated the included studies, and extracted the relevant data. The data included year of publication, country of origin, publication language, publication format (full-text article, short report, letter to the editor, abstract form), type of study (cross-sectional study enrolling a control group, case-control study, cohort 
| Statistical analysis
We extracted data into 2 9 2 contingency tables to generate odds ratios (OR) and 95% confidence intervals (CI). Anticipating heterogeneity across studies' populations and settings, odds ratios were pooled using the random effects model as described by DerSimonian and Laird. 16 Risk difference of HEV seroprevalence in patients on maintenance HD vs control groups was also determined.
Heterogeneity between the studies was evaluated using the 4 | RESULTS
| Studies characteristics
The flow diagram of the study selection is shown in Figure 1 and Figure S8 . We identified 31 studies from 17 countries between 1994 and 2016 that met the selection criteria. 6, [8] [9] [10] [11] One of the identified publications (Dalekos et al.
9
) was considered as two studies as it presented data emanating from two regions in Greece, making the total count of analysed studies included in the meta-analysis 32.
There were 29 cross-sectional studies and two case-control studies. Serial testing at 0-6-12 months was performed in the first prospectively designed case-control study of Ayoola et al 32 in
patients and control groups but the results of control group were reported only once. We considered this study as cross-sectional and we reported the results of both groups at the comparable point of time. Initial testing was performed at different dates over several years in the second retrospectively designed case-control study of Mitsui et al 36 which make comparison between the two groups inaccurate. We considered this study as cross-sectional and we reported the results when they were available for both groups at the same time point.
We excluded 10 duplicated studies and 31 cross-sectional that did not have a control group (references available from the corresponding author). We were not able to obtain the abstract of a cross-sectional study enrolling a control group. 43 
| Characteristics of controls and patients
There were in total 11 158 individuals in the control groups (Table S4 ). The median number of included individuals in the control groups was 212 (range 32-2636). There was more than one group of controls in five studies, 6, 18, 31, 32, 35 and we compared the results of HD patients in these studies with one control group (healthy population, healthy volunteers, or blood donors). The control group was selected from medical staff, out-patients visiting the hospital for blood tests, and in-patients without history of liver or renal disease in three studies. 36, 37, 41 The control group was adjusted for age and sex to patients on HD in four studies, 6, 32, 17, 33 and randomly selected from a large group in one study. 10 There were in total 4817 patients in the HD groups (Table S4 ).
The median number of included patients in the HD groups was 92
(range 38-420). The number of HD centres which participated in each study ranged from 1 to 6. All patients undergoing HD were enrolled in 5 studies 9, 11, 37, 41, 42 ; nonconsecutive patients were enrolled in the Epirus region study of Dalekos et al, 9 whereas these data were missing in the remaining studies. The number of HD patients who had received blood transfusion was reported in 6 studies and ranged from 10% to 77%. The duration of HD in patient groups was reported in 10 studies with an average duration of 58.7 months (range 1-572).
| HEV assays applied in included studies
Anti-HEV IgG was tested by nine different commercial assays (Table S5 ). The Wantai assay was applied in three studies, Abbott Anti-HEV IgM was tested in 15 studies (Table S5) : in all patients and controls in seven studies, 6, 17, 32, 35, 36, 42, 44 when anti-HEV IgG was positive in patients and controls in six studies 9, 18, 19, 21, 30, 41 in selected cases in one study, 8 and when IgG was positive in patients in one study. 37 Eight different commercial assays were used for testing anti-HEV IgM in the included studies. The Wantai assay was applied in two studies 17, 37 and other assays were applied in 13 studies. Confirmation of anti-HEV IgM results was performed in six of the 13 studies (46%), which did not apply the Wantai assay by repeating the test or applying another assay when the test was positive.
In the study of Ricco et al 42 which compared a newly developed total anti-HEV and an anti-HEV IgA assays (Dia.Pro, Italy) to referenced commercially available assays (Wantai for IgG and Dia.Pro for IgM), we reported the results of the referenced assays given that the results of these new assays were not confirmed in other studies.
| Assessment of methodological quality of included studies
By applying the adapted Newcastle Ottawa Scale for cross-sectional studies, 16 studies were judged to have adequate quality and 15 to have moderate limitations (Tables S3 and S6) . Agreement between the reviewers in assessing the methodological quality was evaluated with inter-rater reliability of 97%.
| Seroprevalence of HEV infection in patients
on HD vs control groups (Table 1 and Table S6) Haemodialysis patients were more than twice as likely to have positive IgG for HEV (OR 2.47, 95% CI 1.79-3.40). This analysis was associated with significant heterogeneity (I 2 = 75%, P < .10). Forest plot is depicted in Figure 2 . The absolute difference in IgG seroprevalence between patients on HD and controls was 6% (95% CI 3-9%) ( Figure S1 ). To explore heterogeneity, we conducted several stratified analyses that all showed the same results (OR between of the sensitivity of the assay (low or high sensitivity, P = .59), type of the assay (Abbott EIA or other assays, P = .5), study setting (highly endemic or endemic/non-endemic, P = .53), study methodological quality (adequate quality or moderate limitations, P = .9) or publication status (full-text or non-full-text, P = .45) (Table 1 and Figures S2A, S2B, S3-S5). Egger regression test did not suggest publication bias (P = .83), which was also assessed in a funnel plot ( Figure S7 ).
| Diagnosis of acute hepatitis E in patients on maintenance HD versus control groups
Seven studies reported the results of anti-HEV IgM in all HD patients and controls (Table S7 and Figure S6 ). The odds of IgM seroprevalence were higher in patients on HD (OR = 3.97, 95% CI 1.03-15.24). This analysis was associated with moderate heterogeneity and with wide confidence intervals due to the small number of events. Data were insufficient to conduct subgroup analyses and evaluate heterogeneity.
Hepatitis E virus ribonucleic acid was tested, using nested realtime polymerase chain reaction, in 4 patients who contracted HEV infection after the start of HD in the retrospectively designed case-control study of Mitsui et al, 36 when anti-HEV IgG or IgM were positive in patients and controls in 3 studies, 41, 42, 44 and when anti-HEV IgG or IgM were positive in HD patients in one study. 37 HEV ribonucleic acid was performed in 37 controls and 145 patients and was positive in four and 14 of them respectively (Table S8) . Importantly, liver enzymes were not elevated in the majority of those with positive PCR testing, indicating occult HEV infection. 45 
| Reported risk factors of HEV infection in patients on HD in univariate and multivariate analysis
The reported risk factors of HEV infection in patients on HD in univariate analysis are shown in Table S9 . patients by univariate analysis could be drawn from these results.
The reported risk factors of HEV infection in patients on HD in
multivariate analysis is shown in Table S10 . Four studies reported adjusted odds ratio for age, sex, history of blood transfusion, age at dialysis initiation, number of HD session per week, and duration of HD. Given that the majority of studies did not report adjusted odds ratio of risk factors for HEV transmission in HD patients, no definite conclusion could be drawn from these results.
| DISCUSSION
Hepatitis E virus infection can be a serious disease, with manifestations ranging from acute liver failure, to acute-on-chronic liver failure or chronic hepatitis in immunosuppressed patients. 4 Hepatitis E virus infection antibody assays have wide range of sensitivities and specificities and vary in their performance. However, a novel assay from China (Wantai) has been reported to have a high sensitivity and specificity, and is favoured by many investigators. 57 This assay has moderate diagnostic sensitivity in immunocompromised patients 58 but has not been evaluated specifically in HD patients. Dialysis-dependent patients suffer from cellular and humoral immunocompromise, and results of any immunoglobulinbased assay in this context may underestimate the frequency of infection and should be cautiously interpreted. 37 Furthermore, the immunosuppressed status may result in prolonged seronegative period after infection. Therefore, consideration for molecular-based diagnostic tests may need to be considered tools to better evaluate this viral infection.
The presence of anti-HEV IgG alone is a marker of past infection and reflects the seroprevalence rate in a given population, and could also be present in patients with chronic hepatitis E infection. The seroprevalence of HEV was 6% higher in HD patients compared to controls (95% CI 3-9%), reflecting a clinically significant change in risk.
Acute hepatitis E in HD patients is likely under-diagnosed, 32 Hepatitis E virus ribonucleic acid is the gold standard for diagnosis of ongoing infection. Most of the included studies did not evaluate ribonucleic acid viraemia. Of those that evaluated it, a clear algorithm for ribonucleic acid testing was not described (Table S7 ).
More data is needed assessing the prevalence of true viraemia in this population to understand transmission risk, and to better identify patients at high risk for acute hepatitis pre-and post-renal transplant.
The risk factors for HEV acquisition in HD patients are not fully understood. In addition to HD itself, these patients are more susceptible to infections due to their impaired immunity, and are more likely to receive blood transfusions considering defects in erythropoiesis, which has been demonstrated to increase HEV infection risk. 5, 59 Common bathrooms in the HD units could be a factor for HEV transmission. Furthermore, certain dialysis-specific routes may be in play, such as porcine-derived heparin, which has been implicated as a theoretical source of transmission but has not been yet confirmed. 60 The awareness of HEV as an important public health disease is rising, and it does entail serious morbidity and mortality for certain subsets of patients. Chronic hepatitis E was not reported in patients in this review but the aim of included studies was not to detect chronic hepatitis E. To date, the risk of HEV-related chronic liver disease or cirrhosis in patients on HD is unknown. We currently have non-invasive means of early detection of this infection with sensitive and specific assays, and the benefits of such testing clearly outweigh its risks. The cost-effectiveness of such approach, however, remains to be elucidated. However, statistical modelling could not be performed due to the absence of individual patient data. Third, control group selection was not consistent in some studies. Importantly, the control groups were not representative of the general population in three studies 37,41,63 ; however, HEV seroprevalence was significantly increased in HD groups in two of them. In addition, only four studies matched controls for age and gender. 32, 33, 64 This is important since some epidemiological studies revealed increased HEV seroprevalence in the general population with older age. 54 Interestingly, HEV seroprevalence was significantly increased in the HD group in two of the matched controls studies, 6,64 whereas acute hepatitis E was significantly increased in a third study. 32 Fourth, our assessment of methodological quality of included studies by applying a modified form of the Newcastle Ottawa Scale was not validated, although it was based on a commonly used instrument and included important parameters to fit the question at hand. Fifth, specific HEV transmission risk factors in HD patients were not clearly identified, as they
were not consistently examined across the different studies, and meta-regression analysis was not possible. Sixth, due to the unavailability of individual patient data, we could not calculate adjusted prevalence estimates and resorted to the analysis of crude estimates.
Lastly, data are lacking on the actual impact of hepatitis E on clinical 
